Decision tree stepwise algorithms pointed out the hierarchical power (accuracy = 83%) of IL-6, CCL2, and CXCL8 to sort out patients according to disease outcome.<h4>Conclusions</h4>Overall, these findings support clinical applicability of measuring serum immune mediators as complementary prognostic biomarkers for early classification and prediction of disease outcome in COVID-19 patients. The gene discussed is IL6; the disease is COVID-19.